Valuation: Biogen Inc.

Market Cap 30.6B 26.49B 24.76B 22.63B 42.65B 2,919B 43.32B 290B 114B 1,460B 115B 112B 4,863B P/E 2026 *
36.8x
P/E 2027 * 18.2x
Enterprise Value 35.54B 30.77B 28.76B 26.28B 49.53B 3,390B 50.3B 337B 132B 1,696B 133B 131B 5,648B EV / Sales 2026 *
3.41x
EV / Sales 2027 * 3.11x
Free-Float
85.97%
Yield 2026 *
-
Yield 2027 * -
1 day+1.58%
1 week+2.29%
Current month+1.50%
1 month+3.96%
3 months+9.68%
6 months+11.30%
Current year+20.09%
1 week 176.7
Extreme 176.7
180.74
1 month 165.54
Extreme 165.54
189.72
Current year 134.7
Extreme 134.7
193
1 year 110.1
Extreme 110.1
193
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+2.29% - - 30.72B
+3.02%+6.43%+43.53%+1.90% 78.32B
+0.84%+10.26%-0.15%+27.24% 51.1B
+0.90%+1.67%+22.01%+176.54% 49.18B
+2.33%+8.18%-48.46%-49.18% 44.71B
-0.39%+2.63%+58.51%-23.02% 30.72B
+0.82%+2.63%+55.06%+85.54% 24.44B
+1.08%+8.47%+128.98%-40.36% 23.62B
-0.10%+13.14%+6.63%+202.17% 21.05B
-0.62%+3.30%+65.10%+114.68% 16.61B
Average +1.15%+4.26%+36.80%+55.06% 37.75B
Weighted average by Cap. +1.42%+4.34%+28.63%+43.01%

Financials

2026 *2027 *
Net sales 10.43B 9.03B 8.44B 7.71B 14.54B 995B 14.77B 98.99B 38.84B 498B 39.17B 38.32B 1,658B 10.64B 9.21B 8.61B 7.87B 14.82B 1,014B 15.05B 101B 39.6B 507B 39.93B 39.06B 1,690B
Net income 953M 825M 771M 705M 1.33B 90.9B 1.35B 9.04B 3.55B 45.47B 3.58B 3.5B 151B 1.9B 1.64B 1.54B 1.4B 2.65B 181B 2.69B 18.02B 7.07B 90.62B 7.13B 6.98B 302B
Net Debt 4.94B 4.27B 3.99B 3.65B 6.88B 471B 6.99B 46.84B 18.38B 236B 18.54B 18.13B 784B 2.42B 2.1B 1.96B 1.79B 3.37B 231B 3.43B 22.96B 9.01B 115B 9.09B 8.89B 385B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
10/08/26 EUR 180.08 +1.58% 139
07/08/26 EUR 177.28 +0.33% 158
06/08/26 EUR 176.70 -2.11% 0
05/08/26 EUR 180.50 +5.79% 312
04/08/26 EUR 170.62 -3.08% 30
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
207.13USD
Average target price
235.57USD
Spread / Average Target
+13.73%

Quarterly revenue - Rate of surprise